Anaplastic Thyroid Cancer: An Update

Elsevier

Available online 27 May 2022, 101678

Best Practice & Research Clinical Endocrinology & MetabolismAbstract

Anaplastic thyroid cancer (ATC) is one of the most lethal of all cancers. It is more common in women and occurs primarily in older patients. ATC has a median overall survival of 3-5 months and a nearly 100% disease-specific mortality. It is known to spread rapidly to locoregional structures as well as outside the neck to distant sites, hence ATC is always considered stage IV. With better understanding of the disease at a molecular level, the introduction of newer treatment strategies has been possible and is part of the multimodal (surgery, radiation, and systemic therapy) therapeutic approach. However, there is extensive work needed to achieve better survival outcomes.

Keywords

anaplastic thyroid cancer

undifferentiated

BRAF

targeted therapy

thyroid surgery

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif